Skip to main content
Nathan Steinle, MD, Ophthalmology, Santa Barbara, CA, Goleta Valley Cottage Hospital

NathanChristopherSteinleMD

Ophthalmology Santa Barbara, CA

Retinal Disease

Physician

Dr. Steinle is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Steinle's full profile

Already have an account?

  • Office

    525 East Micheltorena Street
    Suite A
    Santa Barbara, CA 93103
    Phone+1 805-922-2068
    Fax+1 805-965-5214
  • Is this information wrong?

Education & Training

  • Cleveland Clinic Foundation
    Cleveland Clinic FoundationFellowship, Surgical Retina and Vitreous, 2009 - 2011
  • University of Kentucky College of Medicine
    University of Kentucky College of MedicineResidency, Ophthalmology, 2006 - 2009
  • University of Kentucky College of Medicine (Bowling Green)
    University of Kentucky College of Medicine (Bowling Green)Internship, Transitional Year, 2005 - 2006
  • University of South Dakota, Sanford School of Medicine
    University of South Dakota, Sanford School of MedicineClass of 2005

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2011 - 2025
  • SD State Medical License
    SD State Medical License Active through 2025
  • WY State Medical License
    WY State Medical License 2021 - 2024
  • KY State Medical License
    KY State Medical License 2020 - 2022
  • OH State Medical License
    OH State Medical License 2009 - 2012
  • American Board of Ophthalmology Ophthalmology

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • July 29, 2018
    July 29, 2018July 29th, 2018
  • SYFOVRE® (Pegcetacoplan Injection) Continued to Demonstrate Increasing Treatment Effects over 30 Months in Patients with Geographic Atrophy (GA)
    SYFOVRE® (Pegcetacoplan Injection) Continued to Demonstrate Increasing Treatment Effects over 30 Months in Patients with Geographic Atrophy (GA)July 31st, 2023

Hospital Affiliations